IP Library Granted Patent US 12,173,025
Granted Patent B2
US 12,173,025 · App. 17/836,763 · Granted Dec 24, 2024

Substituted nucleosides, nucleotides and analogs thereof

Inventors: Leonid Beigelman (San Mateo, CA); Guangyi Wang (Carlsbad, CA); David Bernard Smith (San Mateo, CA)
Assignee: Janssen Pharmaceuticals, Inc.
C07H19/10A61K31/7076A61P31/14C07H19/06C07H19/16C07H19/173C07H19/20C07H19/207C07H19/213
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,173,025
App. No.
17/836,763
Granted
Dec 24, 2024
Kind
B2
Abstract

Disclosed herein are nucleotide analogs, methods of synthesizing nucleotide analogs and methods of treating diseases and/or conditions such as a HCV infection with one or more nucleotide analogs.

Claims (19)

1. A compound of Formula (I), or a pharmaceutically acceptable salt thereof, having the structure:

wherein:

B 1 is an optionally substituted

R 1 is an optionally substituted C 1-6 alkyl;

R 2 is halo or —OR 7A ;

R 3 is O;

Z p is O;

R p1 is an —O-optionally substituted C 1-6 alkyl;

R 6C is an unsubstituted C 1-6 alkyl, and

R 7A is hydrogen.

2. The compound of claim 1 , wherein R 2 is halo.

3. The compound of claim 2 , wherein R 2 is fluoro.

4. The compound of claim 1 , wherein R 2 is-OR 7A .

5. The compound of claim 4 , wherein R 7A is hydrogen.

6. The compound of claim 1 , wherein R 1 is an optionally substituted ethyl.

7. The compound of claim 6 , having a structure selected from the group consisting of:

or a pharmaceutically acceptable salt of the foregoing.

8. The compound of claim 7 , having a structure selected from the group consisting of:

or a pharmaceutically acceptable salt of the foregoing.

Assignments (6)
CORRECTIVE ASSIGNMENT TO CORRECT THE APPLICANT NAME FROM JANSSEN PHARMACEUTICAL NV TO JANSSEN PHARMACEUTICA NV, AS REFLECTED ON THE ASSIGNMENT DOCUMENT PREVIOUSLY RECORDED ON REEL 67780 FRAME 232. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Jun 26, 2024
From: JANSSEN BIOPHARMA, LLC
To: JANSSEN PHARMACEUTICA NV
Reel/Frame 067923/0001 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 18, 2024
From: BEIGELMAN, LEONID; WANG, GUANGYI; SMITH, DAVID BERNARD
To: ALIOS BIOPHARMA, INC.
Reel/Frame 067762/0889 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 18, 2024
From: JANSSEN PHARMACEUTICA NV
To: JANSSEN PHARMACEUTICALS, INC.
Reel/Frame 067777/0492 →
CHANGE OF NAME Recorded Jun 18, 2024
From: ALIOS BIOPHARMA, INC.
To: JANSSEN BIOPHARMA, INC.
Reel/Frame 067778/0626 →
CHANGE OF NAME Recorded Jun 18, 2024
From: JANSSEN BIOPHARMA, INC.
To: JANSSEN BIOPHARMA, LLC
Reel/Frame 067778/0813 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 18, 2024
From: JANSSEN BIOPHARMA, LLC
To: JANSSEN PHARMACEUTICAL NV
Reel/Frame 067780/0232 →
Continuity (9)
Continuation 17063545 · Oct 5, 2020
Continuation 16692858 · Nov 22, 2019
Continuation 16161705 · Oct 16, 2018
Continuation 15256337 · Sep 2, 2016
Continuation 14836896 · Aug 26, 2015
Continuation 14135484 · Dec 19, 2013
Provisional Application 61890125 · Oct 11, 2013
Provisional Application 61745466 · Dec 21, 2012
Related Publication 20230167151A1 · Jun 1, 2023